{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06343285",
            "orgStudyIdInfo": {
                "id": "20231215"
            },
            "organization": {
                "fullName": "Encora, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Upper Limb Tremor Reduction in Essential Tremor Patients",
            "officialTitle": "Upper Limb Tremor Reduction in Essential Tremor Patients",
            "acronym": "ULTRE",
            "therapeuticArea": [
                "Other"
            ],
            "study": "upper-limb-tremor-reduction-in-essential-tremor-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-26",
            "studyFirstSubmitQcDate": "2024-03-26",
            "studyFirstPostDateStruct": {
                "date": "2024-04-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Encora, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true,
            "isUnapprovedDevice": true,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study is designed to demonstrate the safety and tolerability of the Encora Therapeutics Tremor Mitigation Device in subjects with upper limb tremor caused by Essential Tremor.",
            "detailedDescription": "A prospective, randomized, blinded clinical trial. Subjects meeting all inclusion criteria will have five days of treatment with each of the three arms, received in a randomized order. Subjects will complete two rounds of assessments each day.\n\nArm 1: Inactive stim Arm 2: Stim therapy utilizing a specific dermatome Arm 3: Stim therapy utilizing a tailored frequency"
        },
        "conditionsModule": {
            "conditions": [
                "Essential Tremor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Three different arms in a randomized order",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Randomization schedule maintained by non-Clinical personnel",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1",
                    "type": "SHAM_COMPARATOR",
                    "description": "Inactive stimulation - device is powered on, but motors are inactive and amplitude is set to 0%",
                    "interventionNames": [
                        "Device: Encora Therapeutics Tremor Reduction Device"
                    ]
                },
                {
                    "label": "Arm 2",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Treatment with the wearable device set to a specific dermatome, duty cycle and amplitude",
                    "interventionNames": [
                        "Device: Encora Therapeutics Tremor Reduction Device"
                    ]
                },
                {
                    "label": "Arm 3",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "treatment with the wearable device set to frequency-match the subject's tremor, duty cycle of and amplitude are set",
                    "interventionNames": [
                        "Device: Encora Therapeutics Tremor Reduction Device"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DEVICE",
                    "name": "Encora Therapeutics Tremor Reduction Device",
                    "description": "The proposed therapeutic device uses vibration motors positioned around the wrist that provide on-demand-therapy to suppress resting, postural, or action tremors of the hand.",
                    "armGroupLabels": [
                        "Arm 1",
                        "Arm 2",
                        "Arm 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Tolerability",
                    "description": "The rate of subject-assessed tolerance, on a Subject Stimulation Therapy Tolerance as measured by % of patient who tolerated the treatment either none of the time, some of the time or all of the time.",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "Safety",
                    "description": "The rate of occurrence of adverse events (AEs) as both total numbers of AEs experienced throughout the study and percentage of subjects who experienced an AE.",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Bain & Findley Activity of Daily Living (BF-ADL) #2",
                    "description": "Assess ability to perform daily living activities, score ranges from 1 (without difficulty) to 4 (cannot do by yourself)",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "BF-ADL #4",
                    "description": "Assess ability to perform daily living activities, score ranges from 1 (without difficulty) to 4 (cannot do by yourself)",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "BF-ADL #17",
                    "description": "Assess ability to perform daily living activities, score ranges from 1 (without difficulty) to 4 (cannot do by yourself)",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "BF-ADL #21",
                    "description": "Assess ability to perform daily living activities, score ranges from 1 (without difficulty) to 4 (cannot do by yourself)",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "Patient Global Impression of Change (PGI-C)",
                    "description": "Measures change in condition as compared to baseline, score ranges from 1 = Very much improved to 7 = Very much worse",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "Clinician Global Impression of Change (CGI-C)",
                    "description": "Measures change in condition as compared to baseline, score ranges from 1 = Very much improved to 7 = Very much worse",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "Tremor power as measured by gyroscope",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "The Essential Tremor Rating Scale (TETRAS) #2.4",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "TETRAS #2.6",
                    "description": "The performance section of TETRAS has 9 items rated 0-4 and a maximum total score of 64. Items 1 (head tremor), 2 (face tremor), 3 (voice tremor), 5 (lower limb tremor), 7 (handwriting), and 9 (standing) have maximum scores of 4.",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "TETRAS #2.8",
                    "description": "The performance section of TETRAS has 9 items rated 0-4 and a maximum total score of 64. Items 1 (head tremor), 2 (face tremor), 3 (voice tremor), 5 (lower limb tremor), 7 (handwriting), and 9 (standing) have maximum scores of 4.",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "Patient Global Impression of Severity (PGI-S)",
                    "description": "Rating of condition severity in the past week, score ranges from 1 = Minimal to 5 = Very Severe",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "Clinician Global Impression of Severity (CGI-S)",
                    "description": "Rating of condition severity in the past week, score ranges from 1 = Minimal to 5 = Very Severe",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                },
                {
                    "measure": "Tremor power as measured by accelerometer",
                    "timeFrame": "At the end of the 5-day treatment period in all randomization arms"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion/Exclusion:\n\nInclusion Criteria:\n\n1. Between the ages of 22 and 80 years of age\n2. A diagnosis of essential tremor (definite or probable based on TRIG criteria)\n3. At least one hand exhibiting tremor \\> 2 as assessed by the Essential Tremor Rating\n4. Assessment Scale (TETRAS) finger to nose task, duck wing task, OR Archimedes Spiral completed during the Screening visit\n5. Stable tremor medications for at least 30 days prior to enrollment and the ability to maintain stable medications through the duration of the study\n\nRandomization Inclusion Criteria\n\n1. During the Baseline evaluation period, a median tremor score of \\> 2 on at least one hand as assessed by the TETRAS finger to nose task, the duck wing task, OR the Archimedes Spiral AND\n2. During the Baseline evaluation period, a median score of \\> 3 on any one of the subject-assessed items of the Bain \\& Findley Activities of Daily Living Scale (BF-ADL)\n\nExclusion Criteria:\n\n1. Previous surgical interventions for tremor reduction on the upper limb being used for inclusion in this study (eg, thalamotomy procedure, including Stereotactic Thalamotomy, Gamma Knife Radiosurgical Thalamotomy, or focused ultrasound)\n2. Use of botulinum toxin for treatment to hand tremor within six months of enrollment\n3. Suspected or diagnosed epilepsy or other seizure disorder\n4. Other possible causes of tremor, including Parkinson's disease, drug-induced tremor, or dystonia\n5. Pregnant\n6. Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site\n7. Numbness, tingling or pain affecting the tested upper extremity (eg, suspected or confirmed peripheral neuropathy, carpal tunnel syndrome)\n8. Known allergy to silicone\n9. Subjects are unable or unwilling to comply with the protocol requirements\n10. Subject is part of a vulnerable population who is unable to give Informed Consent for reasons of incapacity, dementia, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent.\n11. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "22 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kristi Winterfeldt, MSHS",
                    "role": "CONTACT",
                    "phone": "7632481210",
                    "email": "kristi@encoratherapeutics.com"
                },
                {
                    "name": "Taylor Robertson",
                    "role": "CONTACT",
                    "phone": "7814221105",
                    "email": "taylor@encoratherapeutics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kristi Winterfeldt, MSHS",
                    "affiliation": "Encora Therapeutics",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Encora Therapeutics",
                    "status": "RECRUITING",
                    "city": "Cambridge",
                    "state": "Massachusetts",
                    "zip": "02139",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kristi Winterfeldt, MSHS",
                            "role": "CONTACT",
                            "phone": "763-248-1210",
                            "email": "kristi@encoratherapeutics.com"
                        },
                        {
                            "name": "Taylor Robertson",
                            "role": "CONTACT",
                            "phone": "7814221105",
                            "email": "taylor@encoratherapeutics.com"
                        },
                        {
                            "name": "Kristi Winterfeldt, MSHS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Fatta Nahab, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.3751,
                        "lon": -71.10561
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014202",
                    "term": "Tremor"
                },
                {
                    "id": "D000020329",
                    "term": "Essential Tremor"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020820",
                    "term": "Dyskinesias"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009069",
                    "term": "Movement Disorders"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16956",
                    "name": "Tremor",
                    "asFound": "Tremor",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22137",
                    "name": "Essential Tremor",
                    "asFound": "Essential Tremor",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22574",
                    "name": "Dyskinesias",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12029",
                    "name": "Movement Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003033",
                    "term": "Coal Tar"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007641",
                    "term": "Keratolytic Agents"
                },
                {
                    "id": "D000003879",
                    "term": "Dermatologic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6263",
                    "name": "Coal Tar",
                    "asFound": "Fail",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10667",
                    "name": "Keratolytic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7074",
                    "name": "Dermatologic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}